Test Overview
Chemiluminescent Immunoassay (CLIA)
Follow-up management of patients undergoing cancer therapy, especially for ovarian carcinoma. Consistently rising CA 125 results may be associated with malignant disease and poor response to therapy; declining values may be indicative of a favorable response to therapy.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
CA 125 concentrations are elevated in 1-2% of healthy individuals and may be elevated in diseases other than ovarian cancer, including benign and malginant disorders. CA 125 is NOT a cancer screening test.
Test Details
4 hours
- Cancer Antigen 125
- DM70K Replacement Assay
- Ovarian Cancer Tumor Marker
Specimen Requirements
Collect specimen in an SST or red top tube. Refrigerate and send intact specimen within 8 hours of collection. Alternatively, centrifuge, aliquot serum into a plastic vial and refrigerate up to 48 hours or freeze for longer storage.
Additional Information
Tested by a chemiluminescent immunoassay manufactured by Siemens Healthineers, performed on Atellica IM system. Results determined from different manufacturers and/or methods may not be comparable.